Heteroaryl-Ethylenes as New Effective Agents for High Priority Gram-Positive and Gram-Negative Bacterial Clinical Isolates

The World Health Organization has identified antimicrobial resistance as a public health emergency and developed a global priority pathogens list of antibiotic-resistant bacteria that can be summarized in the acronym ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacterales species), reminding us of their ability to escape the effect of antibacterial drugs. We previously tested new heteroaryl-ethylene compounds in order to define their spectrum of activity and antibacterial capability. Now, we focus our attention on PB4, a compound with promising MIC and MBC values in all conditions tested. In the present study, we evaluate the activity of PB4 on selected samples of ESKAPE isolates from nosocomial infections: 14 S. aureus, 6 E. faecalis, 7 E. faecium, 12 E. coli and 14 A. baumannii. Furthermore, an ATCC control strain was selected for all species tested. The MIC tests were performed according to the standard method. The PB4 MIC values were within very low ranges regardless of bacterial species and resistance profiles: from 0.12 to 2 mg/L for S. aureus, E. faecalis, E. faecium and A. baumannii. For E. coli, the MIC values obtained were slightly higher (4–64 mg/L) but still promising. The PB4 heteroaryl-ethylenic compound was able to counteract the bacterial growth of both high-priority Gram-positive and Gram-negative clinical strains. Our study contributes to the search for new molecules that can fight bacterial infections, in particular those caused by MDR bacteria in hospitals. In the future, it would be interesting to evaluate the activity of PB4 in animal models to test for its toxicity. View Full-Text

Keywords: ESKAPE; heteroaryl-ethylene; clinical strains; antimicrobial activity

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share and Cite

MDPI and ACS Style

Bivona, D.A.; Mirabile, A.; Bonomo, C.; Bonacci, P.G.; Stracquadanio, S.; Marino, A.; Campanile, F.; Bonaccorso, C.; Fortuna, C.G.; Stefani, S.; Musso, N.; Bongiorno, D. Heteroaryl-Ethylenes as New Effective Agents for High Priority Gram-Positive and Gram-Negative Bacterial Clinical Isolates. Antibiotics 2022, 11, 767. https://doi.org/10.3390/antibiotics11060767

AMA Style

Bivona DA, Mirabile A, Bonomo C, Bonacci PG, Stracquadanio S, Marino A, Campanile F, Bonaccorso C, Fortuna CG, Stefani S, Musso N, Bongiorno D. Heteroaryl-Ethylenes as New Effective Agents for High Priority Gram-Positive and Gram-Negative Bacterial Clinical Isolates. Antibiotics. 2022; 11(6):767. https://doi.org/10.3390/antibiotics11060767

Chicago/Turabian Style

Bivona, Dalida Angela, Alessia Mirabile, Carmelo Bonomo, Paolo Giuseppe Bonacci, Stefano Stracquadanio, Andrea Marino, Floriana Campanile, Carmela Bonaccorso, Cosimo Gianluca Fortuna, Stefania Stefani, Nicolò Musso, and Dafne Bongiorno. 2022. "Heteroaryl-Ethylenes as New Effective Agents for High Priority Gram-Positive and Gram-Negative Bacterial Clinical Isolates" Antibiotics 11, no. 6: 767. https://doi.org/10.3390/antibiotics11060767

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Heteroaryl-Ethylenes as New Effective Agents for High Priority Gram-Positive and Gram-Negative Bacterial Clinical Isolates

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI